[go: up one dir, main page]

WO2001020031A3 - Polymorphisms in a klotho gene - Google Patents

Polymorphisms in a klotho gene Download PDF

Info

Publication number
WO2001020031A3
WO2001020031A3 PCT/GB2000/003457 GB0003457W WO0120031A3 WO 2001020031 A3 WO2001020031 A3 WO 2001020031A3 GB 0003457 W GB0003457 W GB 0003457W WO 0120031 A3 WO0120031 A3 WO 0120031A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphisms
klotho gene
methods
disease
predisposition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003457
Other languages
French (fr)
Other versions
WO2001020031A2 (en
Inventor
Kazuhide Hasegawa
Yasuhiro Kikuchi
Hirofumi Nakano
Helen Molloy
Mathias Chiano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921485.0A external-priority patent/GB9921485D0/en
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to AU70257/00A priority Critical patent/AU7025700A/en
Priority to JP2001523802A priority patent/JP2003514513A/en
Priority to EP00958842A priority patent/EP1210426A2/en
Publication of WO2001020031A2 publication Critical patent/WO2001020031A2/en
Anticipated expiration legal-status Critical
Publication of WO2001020031A3 publication Critical patent/WO2001020031A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)

Abstract

Methods and means are described for diagnosing a disease or a predisposition to disease by genotyping a klotho gene from an individual and identifying the presence of one or more risk polymorphisms. These risk polymorphisms are associated either directly or indirectly with predisposition to a range of chronic diseases including osteoporosis, skin disorders, age-related disease, lung dysfunction and metabolic syndrome. Methods of treatment, kits for diagnostic purposes and an isolated klotho gene including all or some of a range of polymorphisms are also described as well as methods of isolating molecules that modulate a klotho gene.
PCT/GB2000/003457 1999-09-10 2000-09-08 Polymorphisms in a klotho gene Ceased WO2001020031A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU70257/00A AU7025700A (en) 1999-09-10 2000-09-08 Polymorphisms in a klotho gene
JP2001523802A JP2003514513A (en) 1999-09-10 2000-09-08 Polymorphism in the closo gene
EP00958842A EP1210426A2 (en) 1999-09-10 2000-09-08 Polymorphisms in a klotho gene

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9921485.0 1999-09-10
GBGB9921485.0A GB9921485D0 (en) 1999-09-10 1999-09-10 Polymorphisms in a klotho gene
GB0006171A GB0006171D0 (en) 1999-09-10 2000-03-14 Polymorphisms in a klotho gene
GB0006171.3 2000-03-14

Publications (2)

Publication Number Publication Date
WO2001020031A2 WO2001020031A2 (en) 2001-03-22
WO2001020031A3 true WO2001020031A3 (en) 2002-03-14

Family

ID=26243878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003457 Ceased WO2001020031A2 (en) 1999-09-10 2000-09-08 Polymorphisms in a klotho gene

Country Status (4)

Country Link
EP (1) EP1210426A2 (en)
JP (1) JP2003514513A (en)
AU (1) AU7025700A (en)
WO (1) WO2001020031A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112075D0 (en) * 2001-05-17 2001-07-11 Univ Aberdeen Diagnostic method for osteoporosis and related disorders
JP4696294B2 (en) * 2004-08-30 2011-06-08 学校法人慶應義塾 Evaluation method, human estrogen receptor gene, genomic DNA, and diagnostic marker
TWI577387B (en) 2007-04-02 2017-04-11 建南德克公司 Use of KLOTHO BETA
US10555963B2 (en) 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
US20100330062A1 (en) * 2007-05-08 2010-12-30 Koeffler H Phillip Klotho protein and related compounds for the treatment and diagnosis of cancer
US20120014927A1 (en) 2008-12-03 2012-01-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
US8530392B2 (en) 2009-05-13 2013-09-10 Shionogi & Co., Ltd. Test agent for visceral obesity and use thereof
CN102465182A (en) 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 Detection kit for detecting skin active substance and method for detecting skin active substance
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CN109219663A (en) * 2016-06-02 2019-01-15 克洛索治疗有限公司 Therapeutic recombinant KLOTHO proteins and compositions and methods thereof
CN106957921B (en) * 2017-05-18 2020-12-29 中国水产科学研究院珠江水产研究所 SNP locus suitable for klotho gene of micropterus salmoides fed with artificial compound feed and application of SNP locus in breeding
EA035077B1 (en) * 2017-08-14 2020-04-24 Федеральное Государственное Бюджетное Научное Учреждение "Научно Исследовательский Институт Медицины Труда Имени Академика Н.Ф. Измерова" (Фгбну "Нии Мт") Method for predicting the risk of developing syntrophy of bronchial asthma and metabolic syndrome
EP3879271A1 (en) * 2020-03-10 2021-09-15 SALION GmbH Detection of klotho
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BONE (OSAKA) (1999), 13(3), 89-95 *
CHEMICAL ABSTRACTS, vol. 128, no. 18, 4 May 1998, Columbus, Ohio, US; abstract no. 216023, NAGAI, RYOZO ET AL: "Molecular genetics of cardiovascular diseases" XP002172678 *
CHEMICAL ABSTRACTS, vol. 132, no. 12, 20 March 2000, Columbus, Ohio, US; abstract no. 149834, KAWAGUCHI, HIROSHI: "klotho gene and bone metabolism" XP002172677 *
MATSUMURA, Y. ET AL.: "Identification of the Human Klotho Gene and Its Two Transcripts Encoding Membrane and Secreted Klotho Protein", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 242, 1998, pages 626 - 630, XP002172676 *
OGATA, N. ET AL.: "Association of Polymorphism of Human Klotho Locus with Lumbar Spondilosys", J. BONE AND MINERAL RES., vol. 14, no. Suppl.1, 1999, pages S340, XP001010330 *
RINSHO BYORI (1998), 46(3), 249-257 *
YAMASHITA, T. ET AL.: "Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging", J. ENDOCRINOL., vol. 159, 1998, pages 1 - 8, XP002172675 *

Also Published As

Publication number Publication date
AU7025700A (en) 2001-04-17
JP2003514513A (en) 2003-04-22
WO2001020031A2 (en) 2001-03-22
EP1210426A2 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
WO2001020031A3 (en) Polymorphisms in a klotho gene
EP2453024A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2005055808A3 (en) Compositions and methods to diagnose and treat lung cancer
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2005046570A3 (en) Human stem cell materials and methods
WO1999028460A3 (en) Molecules interacting with apoptin
WO2006122046A3 (en) Vascular disease therapies
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
CA2534643A1 (en) Methods for screening and identifying compounds
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO2005016279A3 (en) Melks as modifiers of the rac pathway and methods of use
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
WO2003038130A3 (en) Therapeutics and diagnostics for disorders of erythropoiesis
WO2004094641A3 (en) A novel method of modulating bone-realted activity
WO2001077380A3 (en) Method for predicting predisposition to a disease associated with mutations in a rpgr gene
WO2006009962A3 (en) Acacs as modifiers of the igf pathway and methods of use
WO2007002131A3 (en) Galk1s as modifiers of the pten/akt pathway and methods of use
WO2007063405A3 (en) Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene
WO2000012754A8 (en) Method for identifying substances for the treatment of c-jun-mediated disorders
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
WO2004104171A3 (en) Ranbp2 as modifier of the pten/igf pathway and methods of use
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 523802

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000958842

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000958842

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000958842

Country of ref document: EP